Fenretinide treatment accelerates atherosclerosis development in apoE‐deficient mice in spite of beneficial metabolic effects

MLA

Leonardo Sandrini, et al. “Fenretinide Treatment Accelerates Atherosclerosis Development in ApoE‐deficient Mice in Spite of Beneficial Metabolic Effects.” British Journal of Pharmacology, vol. 177, Nov. 2019, pp. 328–45. EBSCOhost, https://doi.org/10.1111/bph.14869.

APA

Leonardo Sandrini, Giulia Chiesa, Saverio Paltrinieri, Elena Donetti, Silvia S. Barbieri, Fabrizia Bonacina, Eugenio Scanziani, Reijo Laaksonen, Sabina Soldati, Francesca Arnaboldi, Stefano Manzini, Marco Busnelli, & Patrizia Amadio. (2019). Fenretinide treatment accelerates atherosclerosis development in apoE‐deficient mice in spite of beneficial metabolic effects. British Journal of Pharmacology, 177, 328–345. https://doi.org/10.1111/bph.14869

Chicago

Leonardo Sandrini, Giulia Chiesa, Saverio Paltrinieri, Elena Donetti, Silvia S. Barbieri, Fabrizia Bonacina, Eugenio Scanziani, et al. 2019. “Fenretinide Treatment Accelerates Atherosclerosis Development in ApoE‐deficient Mice in Spite of Beneficial Metabolic Effects.” British Journal of Pharmacology 177 (November): 328–45. doi:10.1111/bph.14869.